Open Access

Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment

  • Authors:
    • Rui Xu
    • Tao Yang
    • Bing Yan
    • Junhao You
    • Fang Li
    • Qiang Zuo
  • View Affiliations

  • Published online on: May 5, 2023     https://doi.org/10.3892/ol.2023.13855
  • Article Number: 269
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to investigate the predictive value of pretreatment fibrinogen (FIB) levels in patients with cancer who received immunotherapy as a second‑line treatment. A total of 61 patients with stage III‑IV cancer were included. The cut‑off value of FIB for predicting overall survival (OS) was determined by receiver operating characteristic curve analysis. The prognostic value of pretreatment FIB on progression‑free survival (PFS) and OS was determined by univariate and multivariate analyses. Based on a cut‑off point of 3.47 g/l, patients were divided into low pretreatment FIB (<3.47 g/l) and high pretreatment FIB (≥3.47 g/l) groups. A high pretreatment FIB level was more common in older patients (P=0.03). Kaplan‑Meier analysis showed that patients with high pretreatment FIB levels had shorter PFS and OS times than patients with low FIB levels (P<0.05). In multivariate analysis, pretreatment FIB was an independent prognostic factor for OS [hazard ratio (HR), 6.06; 95% CI, 2.01‑18.28; P<0.01] and OS from the initiation of second‑line treatment (HR, 3.69; 95% CI, 1.28‑10.63; P=0.02). Overall, FIB is associated with survival outcome in patients with cancer who are administered immunotherapy as a second‑line treatment.
View Figures
View References

Related Articles

Journal Cover

June-2023
Volume 25 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xu R, Yang T, Yan B, You J, Li F and Zuo Q: Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment. Oncol Lett 25: 269, 2023.
APA
Xu, R., Yang, T., Yan, B., You, J., Li, F., & Zuo, Q. (2023). Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment. Oncology Letters, 25, 269. https://doi.org/10.3892/ol.2023.13855
MLA
Xu, R., Yang, T., Yan, B., You, J., Li, F., Zuo, Q."Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment". Oncology Letters 25.6 (2023): 269.
Chicago
Xu, R., Yang, T., Yan, B., You, J., Li, F., Zuo, Q."Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment". Oncology Letters 25, no. 6 (2023): 269. https://doi.org/10.3892/ol.2023.13855